Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM106 gene therapy in X-linked chronic granulomatous disease
NCT00778882Phase 2Withdrawn
- Sponsor
- Helixmith
- Start
- Jan 2007
- Primary completion
- Oct 2008
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VM106 in chronic granulomatous disease (CGD), sponsored by Helixmith. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Jan 2007; status: withdrawn.
02
Drugs
VM106
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT00778882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778882.